市場調查報告書

尋常型天皰瘡 (PV):流行病學的預測 (2030年)

Pemphigus Vulgaris (PV) - Epidemiology Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 955869
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
尋常型天皰瘡 (PV):流行病學的預測 (2030年) Pemphigus Vulgaris (PV) - Epidemiology Forecast-2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

全球主要7個國家的尋常型天皰瘡 (PV)的已受診發病數量,2017年達到了41,217件。隨著人口高齡化的發展,患者數有增加趨勢。在各國發病數量佔有率中,美國是32.81% (13,526件),歐洲是60.10%,日本是7.09%。男女中女性比率變高,不過,不知道關於其原因。

本報告提供全球主要7個國家 - 美國,歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國),日本 - 的尋常型天皰瘡 (PV)的疫情趨勢 (發病數量/患病人數) 與今後的預測相關分析,各年齡、男女、各重症度詳細趨勢,及主要推動及阻礙市場要素,相關法規的整頓現狀,臨床開發狀況等資訊彙整,為您概述為以下內容。

目錄

第1章 主要考察

第2章 尋常型天皰瘡 (PV):摘要整理

第3章 尋常型天皰瘡 (PV):流行病學的概要

  • 患者佔有率結構 (2017年)
  • 患者佔有率結構 (2030年)

第6章 疾病的背景和概要:尋常型天皰瘡 (PV)

  • 簡介
  • 臨床症狀
  • 病因
  • PV的症狀
  • 病理生理學
  • PV的診斷方法

第5章 病例報告

  • 尋常型天皰瘡造成的指甲疾病
  • 尋常型天皰瘡的管理:病例報告和臨床更新
  • 46歲的男性的尋常型天皰瘡和全身性紅斑性狼瘡
  • 併發了葉狀天皰瘡和尋常型天皰瘡的1例
  • 臨床性特徵,從組織學的觀察,及尋常型天皰瘡向葉狀天皰瘡抗原簡介的變化 - 2個案例研究

第6章 流行病學和患者人口

  • 主要的分析結果
  • 專家 (KOL)的見解
  • 流行病學的分析技術
  • 尋常型天皰瘡 (PV)的已受診患者數 (主要7個國家的情況)

第7章 美國的流行病學的趨勢

  • 前提條件與根據
  • 尋常型天皰瘡 (PV)的已受診患者總數
  • 尋常型天皰瘡 (PV)的已受診患者數:男女
  • 尋常型天皰瘡 (PV)的已受診患者數:各年齡
  • 尋常型天皰瘡 (PV)的已受診患者數:各重症度

第8章 (EU5)的流行病學的趨勢歐洲主要5個國家

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第9章 日本的流行病學的趨勢

第10章 附錄

第11章 參考文件

第12章 DelveInsight的服務內容

第13章 免責聲明

第14章 關於DelveInsight

目錄
Product Code: DIEI0940

DelveInsight's 'Pemphigus Vulgaris (PV)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the PV, historical and forecasted epidemiology as well as the PV trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Pemphigus Vulgaris (PV) Disease Understanding

Pemphigus Vulgaris (PV) is defined as a potentially fatal, autoimmune and intraepithelial disease characterized by flaccid blisters, and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.

PV is subdivided into two subtypes: mucosal-dominant type and mucocutaneous type. The mucosal-dominant type of PV shows blisters mainly and erosive lesions on the oral mucosa while mucocutaneous type also shows flaccid bullae and intractable erosions of the skin. PV is further segmented based on the severity of the disease as mild, moderate and severe.

Pemphigus Vulgaris (PV) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Pemphigus Vulgaris (PV) Detailed Epidemiology Segmentation

  • The increasing geriatric population and rising prevalence of PV generates a large patient population in the 7MM. In 2017, the diagnosed prevalent population of PV in the 7MM was 41,217.
  • The United States contributes the largest share with 13,526 cases in 2017 acquiring near about 32.81% of the totals 7MM share. On the other hand, EU5 and Japan account for 60.10% and 7.09% diagnosed prevalent population share respectively in 2017.
  • A female predominance in PV is well established. However, the genetic and physiological basis for this gender bias is not well understood. In 2017, males and females contribute to 5,275 and 8,251 diagnosed prevalent cases in the US.
  • DelveInsight's epidemiology model for PV estimates that out of the total diagnosed prevalent population of 13,526 cases in the US for PV in 2017, 5,814 cases are of mild, 3,678 cases are of moderate, and 4,034 accounted for severe cases, respectively.
  • The majority of the PV cases were found in adults between 60-70 years of age. In 2017, 3,014 cases, 2,449 cases, were contributed by patients age 60-69 years, 70-79 years, and lowest cases observed in the age-group of 0-17 years (406 cases) in 2017, respectively in the US.

Scope of the Report:

  • The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of PV.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV.

Report Highlights:

  • 11-Year Forecast of PV
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of PV
  • Gender-specific Diagnosed Prevalent Population of PV
  • Severity-specific Diagnosed Prevalent Population of PV
  • Age-specific Diagnosed Prevalent Population of PV

Key Questions Answered

  • What is the disease risk, burden and unmet needs of PV?
  • What is the historical PV patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of PV at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PV?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of PV during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The PV report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM PV epidemiology forecast.
  • The PV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The PV epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Pemphigus Vulgaris (PV)

3. Pemphigus Vulgaris (PV) Epidemiology Overview at a Glance

  • 3.1. Epidemiology Share (%) Distribution of PV in 2017
  • 3.2. Epidemiology Share (%) Distribution of PV in 2030

4. Disease Background and Overview: Pemphigus Vulgaris (PV)

  • 4.1. Introduction
  • 4.2. Clinical Manifestations
  • 4.3. Disease Causes
  • 4.4. Symptom of PV
  • 4.5. Pathophysiology
  • 4.6. PV Diagnosis
    • 4.6.1. Diagnosis of Pemphigus Vulgaris: Recommendations by an International Panel of Experts
    • 4.6.2. Pemphigus S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

5. Case Reports

  • 5.1. Nail disease in Pemphigus Vulgaris
  • 5.2. Management of oral pemphigus vulgaris: A case report and a clinical update
  • 5.3. Pemphigus Vulgaris and systemic lupus erythematosus in a 46 years old man
  • 5.4. A case of concomitant pemphigus foliaceus and oral pemphigus vulgaris
  • 5.5. A shift in clinical features, histologic findings and antigen profiles from Pemphigus Vulgaris to pemphigus foliaceus - two case studies

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. KOL Views
  • 6.3. Epidemiology Methodology
  • 6.4. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the United States
  • 7.3. Gender-specific Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the United States
  • 7.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United States
  • 7.5. Severity-specific Diagnosed Prevalent Population of Pemphigus Vulgaris in the United States

8. EU5 Epidemiology

  • 8.1. Germany Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Germany
    • 8.1.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
    • 8.1.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
    • 8.1.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
  • 8.2. France Epidemiology
    • 8.2.1. Assumptions and Rationale
    • 8.2.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in France
    • 8.2.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
    • 8.2.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
    • 8.2.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
  • 8.3. Italy Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Italy
    • 8.3.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
    • 8.3.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
    • 8.3.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
  • 8.4. Spain Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Spain
    • 8.4.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
    • 8.4.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
    • 8.4.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
  • 8.5. United Kingdom Epidemiology
    • 8.5.1. Assumptions and Rationale
    • 8.5.2. Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the UK
    • 8.5.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the UK
    • 8.5.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United Kingdom
    • 8.5.5. Severity-Specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United Kingdom

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Japan
  • 9.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan
  • 9.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan
  • 9.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan

10. Appendix

11. Bibliography

  • 11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables

  • Table 1 Summary of Pemphigus Vulgaris (PV), Epidemiology and Key Events (2017-2030)
  • Table 2 Drugs associated with PV
  • Table 3 Association of non-HLA genes with PV
  • Table 4 Differential diagnosis of oral lesions in PV
  • Table 5 PV diagnostic algorithm
  • Table 6 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM (2017-2030)
  • Table 7 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the US (2017-2030)
  • Table 8 Gender-specific Diagnosed Prevalence of PV in the US (2017-2030)
  • Table 9 Age-specific Diagnosed Prevalence of PV in the US (2017-2030)
  • Table 10 Severity-specific Diagnosed Prevalence of PV in the US (2017-2030)
  • Table 11 Total Diagnosed Prevalent Population of PV in Germany (2017-2030)
  • Table 12 Gender-Specific Diagnosed Prevalence of PV in Germany (2017-2030)
  • Table 13 Age-specific Diagnosed Prevalence of PV in Germany (2017-2030)
  • Table 14 Severity-specific Diagnosed Prevalence of PV in Germany (2017-2030)
  • Table 15 Diagnosed Prevalent Population of PV in France (2017-2030)
  • Table 16 Gender-specific Diagnosed Prevalence of PV in France (2017-2030)
  • Table 17 Age-specific Diagnosed Prevalence of PV in France (2017-2030)
  • Table 18 Severity-specific Diagnosed Prevalence of PV in France (2017-2030)
  • Table 19 Diagnosed Prevalent Population of PV in Italy (2017-2030)
  • Table 20 Gender-specific Diagnosed Prevalence of PV1 in Italy (2017-2030)
  • Table 21 Age-specific Diagnosed Prevalence of PV in Italy (2017-2030)
  • Table 22 Severity-specific Diagnosed Prevalence of PV in Italy (2017-2030)
  • Table 23 Diagnosed Prevalent Population of PV in Spain (2017-2030)
  • Table 24 Gender-specific Diagnosed Prevalence of PV in Spain (2017-2030)
  • Table 25 Age-specific Diagnosed Prevalence of PV in Spain (2017-2030)
  • Table 26 Severity-specific Diagnosed Prevalence of PV in Spain (2017-2030)
  • Table 27 Diagnosed Prevalence of PV in the UK (2017-2030)
  • Table 28 Gender-Specific Diagnosed Prevalence of PV in the UK (2017-2030)
  • Table 29 Age-specific Diagnosed Prevalence of PV in the UK (2017-2030)
  • Table 30 Severity-Specific Diagnosed Prevalence of PV in the United Kingdom (2017-2030)
  • Table 31 Diagnosed Prevalent Population of PV in Japan (2017-2030)
  • Table 32 Gender-specific Diagnosed Prevalence of PV in Japan (2017-2030)
  • Table 33 Age-specific Diagnosed Prevalence of PV in Japan (2017-2030)
  • Table 34 Severity-specific Diagnosed Prevalence of PV in Japan (2017-2030)

List of Figures

  • Figure 1 Typical features of a patient with PV
  • Figure 2 Clinical manifestations of Pemphigus
  • Figure 3 World map showing association of type II HLA genes with PV in different populations, grouped according to geographical regions
  • Figure 4 Pathogenesis of Pemphigus
  • Figure 5 Mechanisms of Acantholysis
  • Figure 6 B-cell and T-cell responses in Pemphigus
  • Figure 7 A multi-step approach for diagnosing PV
  • Figure 8 Pemphigus area and activity score
  • Figure 9 Pemphigus activity score
  • Figure 10 Pemphigus Disease Area Index
  • Figure 11 Pemphigus Vulgaris Lesion Severity Score
  • Figure 12 Harman's Pemphigus Grading
  • Figure 13 Kumar's Scoring system
  • Figure 14 Mahajan's Scoring system
  • Figure 15 Diagnostic recommendations for PV by the International Panel of Experts
  • Figure 16 US KOL Views
  • Figure 17 Europe KOL Views
  • Figure 18 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM (2017-2030)
  • Figure 19 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the US (2017-2030)
  • Figure 20 Gender-Specific Diagnosed Prevalence of PV in the US (2017-2030)
  • Figure 21 Age-specific Diagnosed Prevalence of PV in the US (2017-2030)
  • Figure 22 Severity -specific Diagnosed Prevalence of PV in the US (2017-2030)
  • Figure 23 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Germany (2017-2030)
  • Figure 24 Gender-Specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany (2017-2030)
  • Figure 25 Age-specific Diagnosed Prevalence of PV in Germany (2017-2030)
  • Figure 26 Severity-specific Diagnosed Prevalence of PV in Germany (2017-2030)
  • Figure 27 Diagnosed Prevalent Population of PV in France (2017-2030)
  • Figure 28 Gender-specific Diagnosed Prevalence of PV in France (2017-2030)
  • Figure 29 Age-specific Diagnosed Prevalence of PV in France (2017-2030)
  • Figure 30 Severity-specific Diagnosed Prevalence of PV in France (2017-2030)
  • Figure 31 Diagnosed Prevalent Population of PV in Italy (2017-2030)
  • Figure 32 Gender-specific Diagnosed Prevalence of PV in Italy (2017-2030)
  • Figure 33 Age-specific Diagnosed Prevalence of PV in Italy (2017-2030)
  • Figure 34 Severity-specific Diagnosed Prevalence of PV in Italy (2017-2030)
  • Figure 35 Diagnosed Prevalent Population of PV in Spain (2017-2030)
  • Figure 36 Gender-specific Diagnosed Prevalence of PV in Spain (2017-2030)
  • Figure 37 Age-specific Diagnosed Prevalence of PV in Spain (2017-2030)
  • Figure 38 Severity-specific Diagnosed Prevalence of PV in Spain (2017-2030)
  • Figure 39 Diagnosed Prevalence of PV in the UK (2017-2030)
  • Figure 40 Gender-Specific Diagnosed Prevalence of PV in the UK (2017-2030)
  • Figure 41 Age-Specific Diagnosed Prevalence of PV in the UK (2017-2030)
  • Figure 42 Severity-specific Diagnosed Prevalence of PV in the United Kingdom (2017-2030)
  • Figure 43 Diagnosed Prevalent Population of PV in Japan (2017-2030)
  • Figure 44 Gender-specific Diagnosed Prevalence of PV in Japan (2017-2030)
  • Figure 45 Age-specific Diagnosed Prevalence of PV in Japan (2017-2030)
  • Figure 46 Severity-specific Diagnosed Prevalence of PV in Japan (2017-2030)